ישראל - עברית - Ministry of Health

bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 4 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 8 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 16 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - candesartan cilexetil - טבליה - candesartan cilexetil 16 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function (left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated

ישראל - עברית - Ministry of Health

unipharm ltd, israel - candesartan cilexetil - טבליה - candesartan cilexetil 8 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function (left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated

ישראל - עברית - Ministry of Health

dexcel ltd, israel - captopril - טבליה - captopril 12.5 mg - captopril - ace inhibitors, plain - hypertension, congestive heart failure, insulin dependent diabetic nephropathey in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.left ventricular dysfunction after myocardial infarction. captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction < or equals to 40 % and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

ישראל - עברית - Ministry of Health

sanofi israel ltd - ramipril - טבליה - ramipril 1.25 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

ישראל - עברית - Ministry of Health

sanofi israel ltd - ramipril - טבליה - ramipril 2.5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

ישראל - עברית - Ministry of Health

sanofi israel ltd - ramipril - טבליה - ramipril 5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.